IP Library Patent Application 13808515
Patent Application
App. No. 13/808,515

TRANS-EPITHELIAL OSMOTIC COLLYRIUM FOR THE TREATMENT OF KERATOCONUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/808,515
Abstract

Trans-epithelial osmotic collyrium for the treatment of keratoconus by corneal cross-linking with UV rays, of the type consisting of a riboflavin-based solution and an absorption enhancement adjuvant consisting of benzalkonium chloryde (BAC). The solution has a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution and contains a BAC concentration accordingly ranging between 0.005% and 0.035%.

Claims (9)

1 . A trans-epithelial osmotic collyrium for treating keratoconus by corneal cross-linking with UV rays, comprising: a riboflavin-based solution with absorption enhancement adjuvants, wherein said solution is a hypo-osmolar solution with a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution.

2 . The trans-epithelial osmotic collyrium as claimed in claim 1 , wherein said absorption enhancement adjuvants comprise benzalkonium chloride (BAC), in an amount ranging between 0.005% and 0.035%.

3 . The trans-epithelial osmotic collyrium as claimed in claim 2 , wherein said riboflavin-based solution contains a concentration of BAC that varies inversely proportionally with the degree of hypoosmolarity within said ranges.

4 . (canceled)

5 . A method for treating keratoconus, comprising:

applying, to a cornea of an eye without removal of the corneal epithelium, a riboflavin-based solution with absorption enhancement adjuvants, wherein said solution is a hypo-osmolar solution with a hypoosmolarity degree ranging between −70% and −30% over an isotonic solution; and

applying, to said cornea of said eye, UV rays to generate corneal cross-linking with said riboflavin-based solution with said absorption enhancement adjuvants.

6 . The method as claimed in claim 5 , wherein said absorption enhancement adjuvants comprise benzalkonium chloride (BAC), in an amount ranging between 0.005% and 0.035%.

7 . The method as claimed in claim 6 , wherein the riboflavin-based solution contains a concentration of BAC that varies inversely proportionally with the degree of hypoosmolarity within said ranges.

Assignments (2)
SECURITY AGREEMENT Recorded May 10, 2013
From: AVEDRO, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 030391/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2013
From: PINELLI, ROBERTO
To: AVEDRO, INC.
Reel/Frame 029742/0473 →